Total (n = 200) | Hyalgan® (n = 100) | Placebo (n = 100) | p value | |
---|---|---|---|---|
Demographic Characteristic | ||||
Age, mean (SD), yrs | 65.0 (8.3) | 65.9 (8.1) | 64.2 (8.4) | NS |
Sex, n (%) | ||||
Male | 48 (24.0%) | 26 (26.0%) | 22 (22.0%) | NS |
Female | 152 (76.0%) | 74 (74.0%) | 78 (78.0%) | NS |
Weight, mean (SD), kg | 62.7 (10.2) | 63.3 (11.9) | 62.1 (8.3) | NS |
Height, mean (SD), cm | 156.5 (7.2) | 156.8 (7.7) | 156.3 (6.7) | NS |
BMI, mean (SD), kg/m2 | 25.6 (3.6) | 25.7 (4.3) | 25.4 (2.9) | NS |
Disease Characteristic | ||||
Kellgren-Lawrence grade | ||||
Grade II (mild), n (%) | 119 (59.5%) | 59 (59.0%) | 60 (60.0%) | NS |
Grade III (moderate), n (%) | 81 (40.5%) | 41 (41.0%) | 40 (40.0%) | NS |
Duration of OA, mean (SD), days | 427.0 (1022.5) | 499.2 (1190.8) | 354.8 (820.5) | NS |
Clinical Evaluation | ||||
Pain on 50-foot walking test (VAS 0-100 mm) mean (SD) | 46.75 (10.59) | 47.85 (10.76) | 45.65 (10.36) | NS |
WOMAC A-pain (VAS 0-100 mm) mean (SD) | 45.56 (12.12) | 45.73 (11.17) | 45.39 (13.06) | NS |
WOMAC C-function(VAS 0-100 mm) mean (SD) | 45.99 (12.23) | 46.54 (11.31) | 45.45 (13.13) | NS |